$-0.79 EPS Expected for Arsanis, Inc. (ASNS)

July 21, 2018 - By Alicia Butler

Analysts expect Arsanis, Inc. (NASDAQ:ASNS) to report $-0.79 EPS on August, 9.After having $-0.74 EPS previously, Arsanis, Inc.’s analysts see 6.76 % EPS growth. The stock decreased 4.42% or $0.14 during the last trading session, reaching $3.03. About 204,827 shares traded or 126.52% up from the average. Arsanis, Inc. (NASDAQ:ASNS) has 0.00% since July 21, 2017 and is . It has underperformed by 12.57% the S&P500.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address infectious diseases. The company has market cap of $43.31 million. The Company’s lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. It currently has negative earnings. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus.

More notable recent Arsanis, Inc. (NASDAQ:ASNS) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on July 02, 2018, also Schaeffersresearch.com with their article: “2 Healthcare Stocks Getting Buried; Option Bulls Cheer MRVL Spike” published on June 28, 2018, Seekingalpha.com published: “Arsanis to discontinue Phase 2 trial of pneumonia treatment” on June 28, 2018. More interesting news about Arsanis, Inc. (NASDAQ:ASNS) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut” published on July 19, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Novartis Earnings, J&J’s HIV Combo Clears FDA Hurdle, Cara To Offer Shares” with publication date: July 18, 2018.

Arsanis, Inc. (NASDAQ:ASNS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.